Pretreatment of caffeine leads to partial neuroprotection in MPTP model of Parkinson’s disease

Neural Regeneration Research

Volumn 11, Issue 11, 2016, Pages 1750-1751

  Bagga, Puneet ^a   Patel, Anant B ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CAFFEINE; REACTIVE OXYGEN METABOLITE;

AEROBIC METABOLISM; EXCITOTOXICITY; HOMEOSTASIS; HUMAN; LIFE EXPECTANCY; METABOLIC ACTIVITY ASSAY; MOTOR PERFORMANCE; NEUROPROTECTION; NONHUMAN; NOTE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE;

EID: 85006010292     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.4103/1673-5374.194716     Document Type: Note

References (13)

1. Bagga P, Chugani AN, Patel AB (2016) Neuroprotective effects of caffeine in MPTP model of Parkinson’s disease: A13C NMR study. Neurochem Int 92:25-34.
2. Bagga P, Chugani AN, Varadarajan KS, Patel AB (2013) In vivo NMR studies of regional cerebral energetics in MPTP model of Parkinson’s disease: recovery of cerebral metabolism with acute levodopa treatment. J Neurochem 127:365-377.
3. Chang L, Munsaka SM, Kraft-Terry S, Ernst T (2013) Magnetic resonance spectroscopy to assess neuroinflammation and neuropathic pain. J Neuroimmune Pharmacol 8:576-593.
4. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68:384-386.
5. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51:83-133.
6. Jenner P (2003) A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD. Neurology 61:S32-38.
7. Kohutnicka M, Lewandowska E, Kurkowska-Jastrzebska I, Członkowski A, Członkowska A (1998) Microglial and astrocytic involvement in a murine model of Parkinson’s disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 39:167-180.
8. Luk KC, Kehm V, Carroll J, Zhang B, O’Brien P, Trojanowski JQ, Lee VM (2012) Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338:949-953.
9. Patel AB, de Graaf RA, Mason GF, Rothman DL, Shulman RG, Behar KL (2005) The contribution of GABA to glutamate/glutamine cycling and energy metabolism in the rat cortex in vivo. Proc Natl Acad Sci U S A 102:5588-5593.
10. Pierri M, Vaudano E, Sager T, Englund U (2005) KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 48:517-524.
11. Prediger RD (2010) Effects of caffeine in Parkinson’s disease: from neuroprotection to the management of motor and non-motor symptoms. J Alzheimers Dis 20 Suppl 1:S205-220.
12. Smeyne RJ, Jackson-Lewis V (2005) The MPTP model of Parkinson’s disease. Brain Res Mol Brain Res 134:57-66.
13. Xu K, Xu YH, Chen JF, Schwarzschild MA (2010) Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson’s disease. Neuroscience 167:475-481.